Anticancer activity of the antibiotic clioquinol

Cancer Research

Volumn 65, Issue 8, 2005, Pages 3389-3395

  Ding, Wei Qun ^a,b   Lin, Bolin ^a   Vaught, Joshua L ^a   Yamauchi, Hanako ^a   Lind, Stuart E ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; CASPASE; CLIOQUINOL; COPPER; COPPER ZINC SUPEROXIDE DISMUTASE; IONOPHORE; IRON; TRANSITION ELEMENT; ZINC;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL DEATH; CELL KILLING; CELL VIABILITY; CHELATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; FLUORESCENCE ANALYSIS; HUMAN; HUMAN CELL; IC 50; MOUSE; NONHUMAN; PRIORITY JOURNAL; XENOGRAFT;

EID: 17144404213     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-3577     Document Type: Article

References (40)

1. Desoize B. Metals and metal compounds in carcinogenesis. In Vivo 2003;17:529-39.
2. Toyokuni S. Iron-induced carcinogenesis: the role of redox regulation. Free Radic Biol Med 1996;20:553-66.
3. Theophanides T, Anastassopoulou J. Copper and carcinogenesis. Crit Rev Oncol Hematol 2002;42:57-64.
4. Brewer GJ. Copper control as an antiangiogenic anticancer therapy: lessons from treating Wilson's disease. Exp Biol Med (Maywood) 2001;226:665-73.
5. Lovejoy DB. Richardson DR. Iron chelators as anti-neoplastic agents: current developments and promise of the PIH class of chelators. Curr Med Chem 2003;10:1035-49.
6. Pan Q, Kleer CG, van Golen KL, et al. Copper deficiency induced by tetrathiomolybdate suppresses tumor growth and angiogenesis. Cancer Res 2002;62:4854-9.
7. Brewer GJ, Dick RD, Grover DK, et al. Treatment of metastatic cancer with tetrathiomolybdate, an anti-copper, antiangiogenic agent: phase I study. Clin Cancer Res 2000;6:1-10.
8. Redman BG, Esper P, Pan Q, et al. Phase II trial of tetrathiomolybdate in patients with advanced kidney cancer. Clin Cancer Res 2003;9:1666-72.
9. Abeysinghe RD, Greene BT, Haynes R, et al. p53-independent apoptosis mediated by tachpyridine, an anti-cancer iron chelator. Carcinogenesis 2001;22:1607-14.
10. Fan L, Iyer J, Zhu S, et al. Inhibition of N-myc expression and induction of apoptosis by iron chelation in human neuroblastoma cells. Cancer Res 2001;61:1073-9.
11. Pan Q, Bao LW, Merajver SD. Tetrathiomolybdate inhibits angiogenesis and metastasis through suppression of the NFκB signaling cascade. Mol Cancer Res 2003;1:701-6.
12. Hollingshead R. The dihalogen and trihalogen derivatives. In: Oxine and its derivatives, vol. III. London: Butterworths Scientific Publications; 1956. p. 740.
13. Tsubaki T, Honma Y, Hoshi M. Neurological syndrome associated with clioquinol. Lancet 1971;1:696-7.
14. Meade TW. Subacute myelo-optic neuropathy and clioquinol. An epidemiological case-history for diagnosis. Br J Prev Soc Med 1975;29:157-69.
15. Cherny RA, Atwood CS, Xilinas ME, et al. Treatment with a copper-zinc chelator markedly and rapidly inhibits β-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 2001;30:665-76.
16. Kaur D, Yantiri F, Rajagopalan S, et al. Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease. Neuron 2003;37:899-909.
17. Regland B, Lehmann W, Abedini I, et al. Treatment of Alzheimer's disease with clioquinol. Dement Geriatr Cogn Disord 2001;12:408-14.
18. Ritchie CW, Bush AI, Mackinnon A, et al. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Aβ amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch Neurol 2003;60:1685-91.
19. Huang P, Feng L, Oldham EA, et al. Superoxide dismutase as a target for the selective killing of cancer cells. Nature 2000;407:390-5.
20. Liu B, Fan Z. The monoclonal antibody 225 activates caspase-8 and induces apoptosis through a tumor necrosis factor receptor family-independent pathway. Oncogene 2001;20:3726-34.
21. Liu B, Fang M, Schmidt M, et al. Induction of apoptosis and activation of the caspase cascade by anti-EGF receptor monoclonal antibodies in DiFi human colon cancer cells do not involve the c-jun N-terminal kinase activity. Br J Cancer 2000;82:1991-9.
22. Liu B, Peng D, Lu Y, et al. A novel single amino acid deletion caspase-8 mutant in cancer cells that lost proapoptotic activity. J Biol Chem 2002;277:30159-64.
23. Sun J, Blaskovich MA, Knowles D, et al. Antitumor efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: combination therapy with the cytotoxic agents cisplatin, Taxol, and gemcitabine. Cancer Res 1999;59:4919-26.
24. Okado-Matsumoto A, Fridovich I. Assay of superoxide dismutase: cautions relevant to the use of cytochrome c, a sulfonated tetrazolium, and cyanide. Anal Biochem 2001;298:337-42.
25. Heikkila RE, Cabbat FS, Cohen G. In vivo inhibition of superoxide dismutase in mice by diethyldithiocarbamate. J Biol Chem 1976;251:2182-5.
26. Walsh CT, Sandstead HH, Prasad AS, et al. Zinc: health effects and research priorities for the 1990s. Environ Health Perspect 1994;102 Suppl 2:5-46.
27. Cohen JJ, Duke RC. Glucocorticoid activation of a calcium-dependent endonuclease in thymocyte nuclei leads to cell death. J Immunol 1984;132:38-42.
28. Schrantz N, Auffredou MT, Bourgeade MF, et al. Zinc-mediated regulation of caspases activity: dose-dependent inhibition or activation of caspase-3 in the human Burkitt lymphoma B cells (Ramos). Cell Death Differ 2001;8:152-61.
29. 2+-induced cell death in vitro and in vivo. J Neurosci Res 2003;74:736-43.
30. Telford WG, Fraker PJ. Preferential induction of apoptosis in mouse CD4+CD8+ α β TCRloCD3 ε lo thymocytes by zinc. J Cell Physiol 1995;164:259-70.
31. Kondoh M, Tasaki E, Araragi S, et al. Requirement of caspase and p38MAPK activation in zinc-induced apoptosis in human leukemia HL-60 cells. Eur J Biochem 2002;269:6204-11.
32. 2+-induced cortical neuronal death. Neuropharmacology 2003;45:420-8.
33. Kim CH, Kim JH, Moon SJ, et al. Pyrithione, a zinc ionophore, inhibits NF-κB activation. Biochem Biophys Res Commun 1999;259:505-9.
34. Kim CH, Kim JH, Hsu CY, et al. Zinc is required in pyrrolidine dithiocarbamate inhibition of NF-κB activation. FEBS Lett 1999;449:28-32.
35. Pommier Y, Sordet O, Antony S, et al. Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks. Oncogene 2004;23:2934-49.
36. Yassin MS, Ekblom J, Xilinas M, et al. Changes in uptake of vitamin B(12) and trace metals in brains of mice treated with clioquinol. J Neurol Sci 2000;173:40-4.
37. Tanaka H, Tamura Z. Analysis of chinoform binding to human serum albumin by an improved partition equilibrium method. J Pharmacobiodyn 1986;9:1015-22.
38. Stehle G, Sinn H, Wunder A, et al. Plasma protein (albumin) catabolism by the tumor itself-implications for tumor metabolism and the genesis of cachexia. Crit Rev Oncol Hematol 1997;26:77-100.
39. Arbiser JL, Kraeft SK, van Leeuwen R, et al. Clioquinol-zinc chelate: a candidate causative agent of subacute myelo-optic neuropathy. Mol Med 1998;4:665-70.
40. Feng P, Li TL, Guan ZX, et al. Direct effect of zinc on mitochondrial apoptogenesis in prostate cells. Prostate 2002;52:311-8.